Alzheimer’s Disease

Next generation tau tracers: [18F]MK-6420 vs [18F]flortaucipir

Ongoing and future efforts in functional genomics in Alzheimer’s disease

Is amyloid load a valid surrogate endpoint for AD clinical trials?

What’s next for clinical trials in Alzheimer’s disease?

Precision medicine in Alzheimer’s treatment: genetics and co-pathologies

Astrocyte biomarkers associated with amyloid-β and tau pathologies

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Performance of plasma p-tau181 as a community-based screening tool for AD clinical trials

Associations between predicted brain age and Alzheimer’s Disease biomarkers

Lipidomics as a tool for dementia research

Can biomarkers help to predict brain age?

Nilotinib: a potential repurposed treatment for Alzheimer’s disease?

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

Personalized approach to dementia prevention and treatment

Can the APOEε4 genotype contribute to tau pathology progression?

The Phase III NILEAD trial: nilotinib as a novel treatment for AD